Zinlirvimab (10-1074) is a humanized IgG1-λ2 monoclonal neutralizing antibody that targets the gp120/CD4 interface on the HIV-1 envelope glycoprotein receptor to effectively prevent viral attachment. Zinlirvimab (10-1074) inhibits the complex process of viral entry into host CD4+ T cells by recognizing and binding to specific conserved epitopes, thereby effectively preventing the Human Immunodeficiency Virus from establishing a productive and systemic infection. Zinlirvimab (10-1074) exhibits a remarkably optimized pharmacological profile with a significantly extended half-life through specialized Fc-region modifications, facilitating its role as a persistent agent for sustained viral suppression.